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The optimal treatment of primary mediastinal large B-cell lymphoma (PMLBCL) is still undefined. In the absence of randomised
studies, we retrospectively analysed: (a) the effectiveness of two chemotherapy regimens (CHOP vs MACOP-B/VACOP-B) in
complete remission (CR) achievement and event-free survival (EFS) and (b) the role of mediastinal involved-field radiotherapy (IF-
RT) as consolidation. From 1982 to 1999, 138 consecutive patients affected by PMLBCL were treated in 13 Italian institutions with
CHOP (43) or MACOP-B/VACOP-B (95). The two groups of patients were similar as regard to age, gender, presence of bulky
mediastinal mass, pleural effusion, stage and international prognostic indexes category of risk. Overall, 75.5% of patients in CR
received IF-RT as consolidation. Complete remission was 51.1% in the CHOP group and 80% in MACOP-B/VACOP-B (Po0.001).
Relapse occurred in 22.7% of CHOP- and in 9.2% of MACOP-B/VACOP-B-treated patients (n.s.). Event-free patients were 39.5% in
CHOP and 75.7% in the MACOP-B/VACOP-B group (Po0.001). The addition of IF-RT as consolidation improved the outcome,
irrespectively of the type of chemotherapy (P¼0.04). At a multivariate analysis, achievement of CR (Po0.0001) and type of CT
(MACOP-B/VACOP-B) retained the significance for OS (P¼0.008) and EFS (P¼0.03). In our experience, MACOP-B/VACOP-B
appears to positively influence OS and EFS in patients affected by PMLBCL, as compared to CHOP. Consolidation IF-RT on
mediastinum further improves the outcome of CR patients.
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PMLBCL is a subtype of diffuse large B-cell lymphoma (DLCL),
recently recognised as a clinical–pathological entity (Harris et al,
1994). It accounts for a percentage between 6 and 13% of DLCLs
(Falini et al, 1995; Cazals-Hatem et al, 1996).
PMLBCL histology is characterised by a diffuse proliferation of
large B cells with prominent, roundish nuclei, clear cytoplasm and
high proliferative index. A thin band of sclerosis often compart-
mentalises neoplastic elements (Menestrina et al, 1986). Lympho-
ma cells are CD45, CD20, CD19 and CD22 positive, while CD5,
CD10, CD21 and HLA-DR are usually absent (Yousem et al, 1985;
Addis and Isaacson, 1986; Moller et al, 1987; Haioun et al, 1989;
Lamarre et al, 1989; Al-Sharabati et al, 1991; van Besien et al,
2001). Expression of CD30 is often present but weak. Surface and
cytoplasmic immunoglobulins are rarely expressed. The thymic
origin of the neoplastic B cells has been proven (Scarpa et al,
1987; Lamarre et al, 1989; Al-Sharabati et al, 1991; Rodriguez et al,
1994).
The high proliferation rate of neoplastic cells (Todeschini et al,
1990; Falini et al, 1995) correlates with the rapid growth and with
the frequent presence of necrotic areas in the lymphoma mass
(Aisenberg, 1999). Sclerosis can explain the frequent persistence of
variable degrees of residual mass even after successful treatment
(Rohatiner et al, 1994).
PMLBCL affects young people with a female prevalence
(Todeschini et al, 1990; Lazzarino et al, 1993; Falini et al, 1995).
Its rapid growth explains the frequent bulky mediastinal mass
infiltrating thoracic structures (pericardium, pleura) and the chest
wall. Vessels are frequently involved, leading to Superior Vena
Cava Syndrome (SVCS) and to thrombosis (Perrone et al, 1986;
Lamarre et al, 1989; Todeschini et al, 1990). Other symptoms at the
onset are chest pain, cough and dyspnea (Lamarre et al, 1989;
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1995). Most cases are stage I–II. When the lymphoma spreads
beyond the diaphragm, it usually involves the kidney and
suprarenal glands (Perrone et al, 1986; Haioun et al, 1989;
Todeschini et al, 1990; Kirn et al, 1993; Lazzarino et al, 1993). Bone
marrow involvement is extremely rare (Cazals-Hatem et al, 1996;
Abou-Ella et al, 1999). Diagnosis is mostly obtained by thor-
acotomy or mediastinoscopy, superficial lymph nodes being rarely
involved.
Most published reports on PMLBCL mainly focus on the
clinical–pathological features, and few papers only analyse the
role of different chemotherapy regimens on the clinical outcome.
As a result, the optimal therapy has not been defined yet, as
pointed out by a recent review (van Besien et al, 2001).
According to literature, CHOP and third-generation regimens,
followed or not by involved-field radiotherapy (IF-RT), are the
most employed combination therapies (Levitt et al, 1982; Jacobson
et al, 1988; Todeschini et al, 1990; Lazzarino et al, 1993; Falini et al,
1995; Cazals-Hatem et al, 1996; Martelli et al, 1998; van Besien et al,
2001).
A possible superiority of third-generation regimens in DLCLs
has not been validated by a large prospective randomised study
(Fisher et al, 1993). However, this study was not specifically
focused on PMLBCLs. By contrast, data from other series suggest
that, in this setting, third-generation therapies (usually MACOP-B
and VACOP-B) may be more effective than CHOP (Levitt et al,
1982; Todeschini et al, 1990; Bertini et al, 1991; Falini et al, 1995;
Cazals-Hatem et al, 1996; Bieri et al, 1999; van Besien et al, 2001;
Zinzani et al, 2001, 2002).
In absence of randomised trials, we retrospectively analysed
a large series of PMLBCL consecutive patients treated with
CHOP or MACOP-B/VACOP-B observed in 13 different Italian
institutions.
The first aim of this analysis was to compare the long-term
results of CHOP vs MACOP-B/VACOP-B, the two most commonly
employed regimens in PMLBCL patients in USA and Europe,
respectively (van Besien et al, 2001). Patients treated with
other regimens and those receiving stem cell transplant (SCT)
as consolidation were not analysed. The two therapeutic
approaches have been compared, taking into account the
recognised international prognostic indexes (IPI) (The Interna-
tional Non-Hodgkin’s Lymphoma Prognostic Factors Project,
1993).
The second objective of our analysis was to evaluate the role
of consolidation IF-RT on the long-term outcome after CR
achievement.
This paper reports our multicentre retrospective experience.
PATIENTS AND METHODS
Patients
Our review includes 138 consecutive patients observed in 13 Italian
institutions between 1982 and 1999. Patients received routine
staging procedures (complete physical examination, laboratory
tests including serum LDH and serum beta-2 microglobulin, chest
X-ray, CT scan of the chest, abdomen and pelvis, bone marrow
aspirate, and biopsy). Stage was defined according to the Ann
Arbor staging system. Bulky disease was defined as a mediastinal
mass larger than 1/3 of thoracic diameter or a mediastinal mass
larger than 10cm (major diameter).
Diagnostic criteria
All biopsy specimens were reviewed and confirmed according
to the WHO criteria for PMLBCL diagnosis. Immunopheno-
typical analysis was always performed. Other NHLs involving
the mediastinum and not fulfilling these criteria were not
considered.
Selection criteria
Only patients treated with CHOP or MACOP-B/VACOP-B were
included in this report. Patients who underwent other regimens or
patients who received SCT after completing CHOP or MACOP-B/
VACOP-B were excluded. Each institution chose treatment (CHOP
or MACOP-B/VACOP-B) according to the local policy at the time.
Chemotherapy was based on six cycles of CHOP or on a full (12
weeks) cycle of MACOP-B/VACOP-B. In each group of therapy,
patients were divided into low/low-intermediate- and high-
intermediate/high-risk groups according to IPI.
Involved-field radiotherapy was administered in patients in
complete remission (CR)/near-complete remission (NCR). The
decision to employ IF-RT or not was made according to the local
policy of each centre. The modality of IF-RT administration was
the following: (a) when the mass involved only the mediastinum,
the whole original disease was irradiated; (b) when the mass
spread beyond the mediastinum displacing the lung, IF-RT was
administered to involve the mediastinum volume plus 1.5cm
outside its borders. The median dosage of IF-RT was 34Gy
(range 30–45). Only patients who underwent IF-RT after achieving
CR or NCR were considered for IF-RT significance on disease
outcome.
Response criteria
CR was defined as the disappearance of lymphoma lesions and
resolution of symptoms for at least 3 months after the end of CT.
Near-complete remission (i.e. unconfirmed CR) was defined as the
reduction of mass (lymphoma lesions) 490%, without new growth
at physical and imaging examination, without signs and symptoms
of disease for at least 3 months. Partial remission (PR) was defined
as reduction of at least 50% of the original measurable mass. No
remission (NR) was defined as (a) minimal modification (a
response less than 50%) or (b) no modification or (c) progression
of the mass under CT or (d) new lymphoma growth during CT or
within 3 months after the end of CT.
In our review, gallium scan could not be considered in the
assessment of CR, since only a minority of patients underwent this
procedure. The possible persistence of some degree of fibrosis after
CT even in responders makes it difficult to define the real
incidence of CR. However, the long-term observation of our study
allowed us to clarify this point, since NR or low responsive cases
had invariably a rapid fatal outcome. Therefore, the long-term EFS
had been judged a posteriori as an indicator of CR achievement. OS
was calculated from the beginning of chemotherapy to the death or
the last follow-up. EFS was defined as survival from the beginning
of chemotherapy, in the absence of unfavourable events such as (1)
toxic death, (2) NR, PR or progression, (3) relapse and (4) death
due to any cause.
Statistical analysis
Statistical analysis was performed using the w
2 test with Yates
correction and with Fisher’s exact test for categorical variables.
Survival curves were calculated from the beginning of the
treatment according to the actuarial method proposed by Kaplan
and Meier. Differences between curves were evaluated by log-rank
test. Cox regression analysis was performed to determine the
independent contribution of the following variables: achievement
of CR, type of treatment (CHOP vs MACOP-B/VACOP-B) and IPI
score (low/low-intermediate vs high-intermediate/high). Each
variable was compared to the previous one.
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lRESULTS
Among the 138 patients, there were 75 females and 63 males (F/M
1.19). The median age was 39 (range 14–70). Only seven out of 138
patients were over 60. Most patients were in stage I–II (95 out of
138: 68.9%); stage III–IV patients were 43 out of 138 (31.1%).
Bulky mediastinal mass was present in 111 out of 138 (80.4%)
and bone marrow involvement in two out of 138 (1.4%) cases. In
all, 15 patients in stage IV had organ involvement beyond the
diaphragm; in 13 (86.6%) of them, renal and suprarenal glands
involvement was present. A total of 43 patients have been treated
with CHOP and 95 with MACOP-B/VACOP-B. According to IPI,
the different risk groups were: low, 82 out of 138 (59.4%); low-
intermediate, 25 out of 138 (18.1%); high-intermediate, 23 out of
138 (16.6%); high, eight out of 138 (5.7%). The two risk categories
were balanced in CHOP- and MACOP-B/VACOP-B-treated groups
(Table 1).
The median follow-up of all entered patients was 66.5 months
(1–199þ). The median follow-up of patients alive in CR was 89.5
months (8–199þ): 78 months (8–199þ) in CHOP- and 91.5
months (10–172þ) in MACOP-B/VACOP-B-treated groups.
The overall CR rate was obtained in 98 out of 138 (70%) and
event-free patients were 89 out of 138 (64.4%). Complete
remission/NCR were 22 out of 43 (51.1%) in the CHOP group
and 76 out of 95 (80%) in the MACOP-B/VACOP-B group
(Po0.0001). No remission/PD were 18 out of 43 (41.8%) and nine
out of 95 (9.4%), respectively (Po0.001). Event-free patients were
17 out of 43 (39.5%) in CHOP- and 72 out of 95 (75.7%) in
MACOP-B/VACOP-B-treated groups (Table 2; Figure 1).
Considering IPI, in low/low-intermediate risk, 17 out of 33
(51.1%) CHOP-treated patients achieved CR, as opposed to 62 out
of 74 (83.7%) MACOP-B/VACOP-B-treated ones (P¼0.001).
Event-free patients were 14 out of 33 (42.4%) and 60 out of 74
(81%), respectively (P¼0.0001) (Table 3). In the small group (31
out of 138, 22.4%) of high-intermediate/high-risk patients, five out
of 10 (50%) CHOP-treated patients achieved CR vs 14 out of 21
(66.6%) MACOP-B/VACOP-B-treated ones (P¼0.068).
Of the 37 patients in stage IV, only 17 (45.9%) became event-free
survivors. Among the 15 patients with organ involvement beyond
the diaphragm (four treated with CHOP, 11 with MACOP-B),
only five (33.3%) were event-free (all treated with MACOP-B/
VACOP-B).
Relapses occurred after a median time of 9 months (range 3–
77), mostly (eight out of 12: 66.6%) within 1 year from CR.
Involved-field radiotherapy was considered for patients in
CR/NCR
The majority of patients who achieved CR with CT received IF-RT
on the mediastinum as consolidation (74 out of 98: 75.5%).
Kaplan–Meier survival curve performed on the population who
achieved CR showed a statistically significant difference in event-
free survival time in patients receiving IF-RT (P¼0.04) (Figure 2).
Considering the achievement of CR, the type of treatment and
the IPI levels as covariates, a multivariate Cox regression analysis
for survival indicated that the achievement of CR and the type of
treatment (MACOP-B/VACOP-B) were statistically significant.
Differences between IPI levels did not achieve this condition
(Table 4).
Table 1 Clinical characters of patients treated with CHOP or MACOP-B/
VACOP-B
CHOP
MACOP-B/
VACOP-B P
Patients 43 95
Median age 35 (17–70) 36.5 (14–65)
Gender (F/M) 27/16 (1.68) 48/47 (1.02)
B symptoms 9/43 (20.9%) 48/95 (50.5%) 0.002
Bulky mediastinum 32/43 (74.4%) 79/95 (83.1%) n.s.
Pleural effusion 19/43 (44.1%) 43/95 (45.2%) n.s.
Pericardial effusion 9/43 (20.9%) 28/95(29.4%) n.s.
SVCS 25/43 (58.1%) 43/95 (45.2%) n.s.
Stage I–II 29/43 (67.4%) 66/95 (69.4%) n.s.
Stage III–IV 14/43 (32.5%) 29/95 (30.5%) n.s.
IPI
Low/low-intermediate 25/39 (64.1%) 62/92 (67.3%) n.s.
High-intermediate/high 14/39 (35.8%) 30/92 (32.6%) n.s.
Study period
1982–1990 26 (60.5%) 45 (47.3%) n.s.
1991–1999 17 (39.5%) 50 (52.6%) n.s.
Median follow-up
(censored patients)
78 mo (8–199+) 91.5 mo (10–172+)
Table 2 Overall results comparing CHOP to MACOP-B/VACOP-B
CHOP MACOP-B/VACOP-B P
Patients 43 95
CR/NCR 22/43 (51.1%) 76/95 (80%) Po0.001
PR 3/43 (6.9%) 10/95 (10.5%) n.s.
NR/PD 18/43 (41.8%) 9/95 (9.4%) Po0.001
REL 5/22 (22.7%) 7/76 (9.2%) n.s.
EFS 17/43 (39.5%) 72/95 (75.7%) Po0.001
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Figure 1 Event-free survival in CHOP- vs MACOP/VACOP-B-treated
patients.
Table 3 Results of CHOP vs MACOP-B/VACOP-B in 138 consecutive
patients according to IPI
CHOP MACOP-B/VACOP-B P
Low/low-intermediate risk
Patients 33/43 (76.7%) 74/95 (77.8%) n.s.
CR/NCR 17/33 (51.5%) 62/74 (83.7%) P¼0.001
PR 1/33 6/74 (8%) n.s.
NR/PD 15/33 (45.4%) 6/62 (9.6%) P¼0.001
REL 3/17 (17.6%) 5/62 (8%) n.s.
Event-free patients 14/33 (42.4%) 60/74 (81%) Po0.001
High-intermediate/high risk
Patients 10/43 (23.2%) 21/95 (22.1%) n.s.
CR/NCR 5/10 (50%) 14/21 (66.6%) n.s.
PR 2/10 (20%) 4/21 (19%) n.s.
NR/PD 3/10 (30%) 3/21 (14.2 %) n.s.
REL 2/5 (40%) 1/21 (4.7%) n.s
Event-free patients 3/10 (30%) 12/21 (57.1%) n.s.
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lDISCUSSION
Our analysis was focused on CHOP vs MACOP/VACOP-B, the
most commonly regimens used in PMLBCL. The long-term
results provided by this retrospective experience indicate that, in
this setting, MACOP-B/VACOP-B achieve better results than
CHOP, and confirm our previous experience (Todeschini et al,
1990). Additional retrospective data are in agreement with our
observation (Bertini et al, 1991; Lazzarino et al, 1993; Falini et al,
1995; Cazals-Hatem et al, 1996; Lazzarino et al, 1997; Martelli et al,
1998; Bieri et al, 1999; Zinzani et al, 2001). Similar results were
recently observed in a large retrospective study (Zinzani et al,
2002), which included patients treated with chemotherapy other
than CHOP or MACOP/VACOP-B. Limiting the observations to
CHOP and third-generation therapies, the authors found a
projected 10-years progression-free survival (PFS) and OS of 35
and 44% with CHOP, and 67 and 71% with third-generation
therapies, respectively.
Although a large randomised study (Fisher et al, 1993) showed no
difference in outcome for intermediate-high-grade NHLs, in that
study, the subgroup of PMLBCL was not separately considered.
In our series, advantages were statistically significant in the
MACOP-B/VACOP-B-treated group at low/low-intermediate risk
(P¼0.001). In the small group of high-intermediate/high-risk
patients, an advantage from MACOP-B/VACOP-B as compared to
CHOP was observed in terms of CR rate and EFS, but it was not
statistically significant (P¼0.068).
Based on the results of our experience, we suggest that
MACOP-B/VACOP-B can be more effective than CHOP in the
treatment of PMLBCL. This assumption is supported by three
observations.
First, although this is a retrospective review, the clinical
characteristics of the two groups of patients were balanced (age,
bulky mediastinum, pleural and pericardial effusion, presence of
SVCS, stage I-II vs III-IV, type of chemotherapy during the study
period) (Table 1).
Second, the IPI risk categories were equally distributed in the
two therapeutic groups (Table 1).
Third, the two CT regimens were administered almost uniformly
in the study time, thus avoiding the occurrence of possible biases
due to different supportive measures.
The achievement of CR was the most significant prognostic
factor both for OS and EFS (Po0.0001) (Table 4). A high
percentage of patients who reached CR remained event-free, thus
suggesting that a therapeutic approach able to increase the CR rate
could influence the long-term OS and EFS. In fact, in both
chemotherapy groups of our series, patients unresponsive or
progressing under CT had invariably a fatal outcome (26 out of 26
died of lymphoma).
Relapse rarely affects PMLBCL patients, although it is the main
cause of failure in other large-cell lymphomas. In our series, a very
poor outcome was observed in the few relapsed patients (12.2%),
since all of them died of lymphoma, independently of first-line
therapy and subsequent salvage approaches (Table 2). Involved-
field radiotherapy was ineffective in controlling the disease
progression too. These findings are in agreement with the majority
of reports (Moller et al, 1987; Jacobson et al, 1988; Cazals-Hatem
et al, 1996; Zinzani et al, 2001), but contrast with the relatively
good results described by other authors (Popat et al, 1998; Sehn
et al, 1998) in small groups of refractory/relapsed patients treated
with stem cell rescue.
In PMLBCL, the dismal outcome of relapsed/refractory patients
seems even worser than in other DLCLs, and it appears as a further
characteristic of this lymphoma entity. In fact, in other aggressive
NHLs, a variable percentage of patients achieve a second CR and a
small but not negligible proportion of them obtain a prolonged
survival.
In our experience, patients with advanced stage of disease (i.e.
subdiaphragmatic organ involvement) had a lower achievement of
CR and a very poor outcome, suggesting that in these patients
more intensive approaches, including stem cell transplantation,
should be early considered.
Consolidation IF-RT is largely employed in PMLBCL patients,
but its role is unclear. In our experience, the administration of IF-
RT after CR achievement showed a positive impact on EFS,
irrespective of the type of chemotherapy administered (P¼0.04)
(Figure 2). The favourable role of IF-RT is suggested by a recent
large retrospective analysis (Zinzani et al, 2002).
The relative high percentage of NR in CHOP-treated patients
and the extremely poor outcome of NR/relapsed patients
suggest that the maximum effort should be done in the early
phase of the disease, given the critical importance of the first-line
therapy.
In fact, at the multivariate analysis, CR achievement and type of
chemotherapy (MACOP-B, VACOP-B) were independent prognostic
factors for EFS, while IPI did not result to be significant (Table 4).
According to these results and in the absence of randomised
studies, MACOP-B/VACOP-B followed by IF-RT should be
provisionally recommended for PMLBCL patients.
Randomised prospective studies are needed to define the
optimal first-line chemotherapy and to assess the role of
mediastinal IF-RT in PMLBCL treatment.
REFERENCES
Abou-Ella AA, Weisenburger DD, Vose JM, Kollath JP, Lynch JC, Bast MA,
Bierman PJ, Greiner TC, Chan WC, Armitage JO (1999) Primary
mediastinal large B-cell lymphoma: a clinicopathologic study of 43 patients
from the Nebraska Lymphoma Study Group. J Clin Oncol 17: 784–790
Addis BJ, Isaacson PG (1986) Large cell lymphoma of the mediastinum: a B-
cell tumor of probable thymic origin. Histopathology 10: 379–390
Aisenberg AC (1999) Primary large cell lymphoma of the mediastinum.
Semin Oncol 26: 251–258
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
P
r
o
p
o
r
t
i
o
n
a
l
 
c
u
m
u
l
a
t
i
v
e
 
s
u
r
v
i
v
a
l
−60 6 1 21 82 43 03 6 4 85 46 06 67 27 88 49 09 6 1 0 2 1 0 8 1 1 4 1 2 0 42
Event-free survival time (months)
P=0.04
IF radiotherapy
No IF radiotherapy
Figure 2 Event-free survival in CR patients treated or not with IF-RT.
Table 4 Multivariate analysis (Cox proportional hazards model) on 138
PMLBCL patients
Covariates P value Coefficient 95% CI
Type of Chemotherapy
(CHOP vs MACOP-B/VACOP-B)
0.027 0.498 0.269–0.923
CR achievement 0.000 11.507 5.378–24.624
IPI level 0.608 1.180 0.626–2.225
Primary mediastinal large B-cell lymphoma, chemotherapy
G Todeschini et al
375
British Journal of Cancer (2004) 90(2), 372–376 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lAl-Sharabati M, Chittal S, Duga-Neulat I, Laurent G, Mazzerolles C, al-Saati
T, Brousset P, Delsol G (1991) Primary anterior mediastinal B-cell
lymphoma. A clinicopathological and immunohistochemical study of 16
cases. Cancer 67: 2579–2587
Bertini M, Orsucci L, Vitolo U, Levis A, Todeschini G, Meneghini V, Novero
D, Tarella C, Gallo E, Luxi G (1991) Stage II large B-cell lymphoma with
sclerosis treated with MACOP-B. Ann Oncol 2: 733–737
Bieri S, Roggero E, Zucca E, Bertoni F, Pianca S, Sanna P, Pedrinis E,
Bernier J, Cavalli F (1999) Leuk Lymphoma 35: 537–544
Cazals-Hatem D, Lepage E, Brice P, Ferrant A, d’Agay MF, Baumelou E,
Briere J, Blanc M, Gaulard P, Biron P, Schlaifer D, Diebold J, Audouin J
(1996) Primary mediastinal large B-cell lymphoma. A clinicopathologic
study of 141 cases compared with 916 non-mediastinal large B-cell
lymphomas, a GELA ("Groupe d’Etude des Lymphomes de l’Adulte")
study. Am J Surg Pathol 20: 877–888
Falini B, Venturi S, Martelli MSantucci A, Pileri S, Pescarmona E,
Giovannini M, Mazza P, Martelli MF, Pasqualucci L, Ballatiori E,
Guglielmi C, Amadori S, Poggi S, Sabattini E, Gherlinzoni F, Zinzani PL,
Baroni CD, Mandelli F, Tura S (1995) Mediastinal large B-cell lymphoma.
Clinical and immunohistological findings in 18 patients treated with
different third-generation regimens. Br J Haematol 89: 780–789
Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick
JH, Coltman CA, Miller TP (1993) Comparison of standard regimen
(CHOP) with three intensive chemotherapy regimens for advanced non-
Hodgkin’s lymphoma. N Engl J Med 328: 1002–1006
Haioun C, Gaulard P, Roudot-Thoraval F, Divine M, Jouault H, Lebourgeois
JP, Kuentz M, Farcet JP, Reyes F (1989) Mediastinal diffuse large-cell
lymphoma with sclerosis. A condition with a poor prognosis. Am J Clin
Oncol 12: 425–429
Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, de
Wolf-Peeters C, Falini B, Gatter KC (1994) A revised European–
American classification of lymphoid neoplasm: a proposal from the
International Lymphoma Study Group. Blood 84: 1361–1391
Jacobson JO, Aisenberg AC, Lamarre L, Willet CG, Linggood RM, Miketic
LM, Harris NL (1988) Mediastinal large cell lymphoma. An uncommon
subset of adult lymphoma curable with combined modality therapy.
Cancer 62: 1893–1898
Kirn D, Mauch P, Shaffer K, Pinkus G, Shipp MA, Kaplan WD, Tung N,
Wheeler C, Beard CJ, Cannellos GP (1993) Large-cell and immunoblastic
lymphoma of the mediastinum. Prognostic and pathologic features in 57
patients. J Clin Oncol 11: 1336–1343
Lamarre L, Jacobson JO, Aisenberg AC, Harris NL (1989) Primary
lymphoma of the mediastinum. A histologic and immunophenotypic
study of 29 cases. Am J Surg Pathol 13: 730–739
Lazzarino M, Orlandi E, Paulli M, Boveri E, Morra E, Brusamolino E, Kindl
S, Rosso R, Astori C, Buonanno MC, Magrini U, Bernasconi C (1993)
Primary mediastinal B-cell lymphoma with sclerosis. An aggressive
tumor with distinctive clinical and pathologic features. J Clin Oncol 11:
2306–2313
Lazzarino M, Orlandi E, Paulli M, Strater J, Klersy C, Gianelli U, Gargantini
L, Rousset MT, Gambacorta M, Marra E, Lavabre-Bertrand T, Magrini U,
Manegold C, Bernasconi C, Moller P (1997) Treatment outcome and
prognostic factors for primary mediastinal (Thymic) B-cell lymphoma: a
multicenter study of 106 patients. J Clin Oncol 15: 1646–1653
Levitt LJ, Aisenberg AC, Harris NL, Linggood RM, Poppema S (1982)
Primary non-Hodgkin’s lymphoma of the mediastinum. Cancer 50:
2486–2492
Martelli MP, Martelli M, Pescarmona E, De Sanctis V, Donato V, Palombi F,
Todisco E, Rensina EA, Pau FM, Mandelli F (1998) MACOP-B and
involved field radiation therapy is an effective therapy for primary
mediastinal large B-cell lymphoma with sclerosis. Ann Oncol 9: 1027–
1029
Menestrina F, Chilosi M, Bonetti F, Lestani M, Scarpa A, Novelli P, Doglioni
C, Todeschini G, Ambrosetti A, Fiore-Donati L (1986) Mediastinal large-
cell lymphomas of B-type, with sclerosis: histopathological and
immunohistochemical study of eight cases. Histopathology 10: 589–600
Moller P, Moldenhauer G, Momburg F, Lammler B, Eberlein-Gonska M,
Kiesel S, Dorken B (1987) Mediastinal lymphoma of clear cell type is a
tumor corresponding to terminal steps of B-cell differentiation. Blood 69:
1087–1095
Perrone T, Frizzera G, Rosai J (1986) Mediastinal diffuse large cell
lymphoma with sclerosis. A clinicopathologic study of 60 cases. Am J
Surg Pathol 10: 176–191
Popat U, Przepiork D, Champlin R, Pugh W, Amin K, Mehra R, Rodriguez
J, Giralt S, Romaguera J, Rodriguez A, Preti A, Andersson B, Khouri I,
Claxton D, de Lima M, Donato M, Anderlini P, Gajewski J, Cabanillas F,
van Besien K (1998) High-dose chemotherapy for relapsed and refractory
diffuse large B-cell lymphoma: mediastinal localization predicts for a
favorable outcome. J Clin Oncol 16: 63–69
Rodriguez J, Pugh WC, Romaguera JE, Luthra R, Hagemeister FB,
McLaughlin P, Rodriguez MA, Swan F, Cabanillas F (1994) Primary
mediastinal large cell lymphoma. Hematol Oncol 12: 175–184
Rohatiner AZ, Whelan JS, Ganjoo RK, Norton AJ, Wilson A, Lister TA
(1994) Mediastinal large-cell lymphoma with sclerosis (MLCLS). Br J
Cancer 69: 601–604
Scarpa A, Bonetti F, Menestrina F, Menegazzi M, Chilosi M, Lestani M,
Bovolenta C, Zamboni G, Fiore-Donati L (1987) Mediastinal large-cell
lymphoma with sclerosis. Genotypic analysis establishes its B-cell nature.
Virchows Arch A. Virchows Arch A Pathol Anat Histopathol 412: 17–21
Sehn LH, Antin JH, Shulman LN, Mauch P, Elias A, Kadin ME, Wheeler C
(1998) Primary diffuse large B-cell lymphoma of the mediastinum:
outcome following high-dose chemotherapy and autologous hemato-
poietic cell transplantation. Blood 91: 717–723
The International Non-Hodgkin Lymphoma Prognostic Factors Project
(1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N
Engl J Med 329: 987–994
Todeschini G, Ambrosetti A, Meneghini V, Pizzolo G, Menestrina F, Chilosi
M, Benedetti F, Veneri D, Cetto GL, Perona G (1990) Mediastinal large B-
cell lymphoma with sclerosis. A clinical study of 21 patients. J Clin Oncol
8: 804–808
van Besien K, Kelta M, Bahaguna P (2001) Primary mediastinal B-cell
lymphoma: a review of pathology and management. J Clin Oncol 19:
1855–1864
Yousem SA, Weiss LM, Warnke RA (1985) Primary mediastinal non
Hodgkin’s lymphomas. A morphologic and immunologic study of 19
cases. Am J Clin Pathol 83: 676–680
Zinzani PL, Martelli M, Bendandi M, De Renzo A, Zaccaria A, Pavone E,
Bocchia M, Falini B, Gobbi M, Gherlinzoni F, Stefoni V, Tani M, Tura S
(2001) Primary mediastinal large B-cell lymphoma with sclerosis: a
clinical study of 89 patients treated with MACOP-B chemotherapy and
radiation therapy. Haematologica 86: 187–191
Zinzani PL, Martelli M, Bertini M, Gianni AM, Devizzi L, Federico M,
Pangalis G, Michels J, Zucca E, Cantonetti M, Cortelazzo S, Wotherspoon
A, Ferreri AJM, Zaja F, Lauria F, De Renzo A, Liberati MA, Falini B,
Balzarotti M, Calderoni A, Zaccaria A, Gentilini P, Fattori PP, Pavone E,
Angelopoulou MK, Alinari L, Brugiatelli M, Di Rienzo N, Bonifazi F,
Pileri SA, Cavalli F (2002) Induction chemotherapy strategies for primary
mediastinal large B-cell lymphoma with sclerosis: a retrospective
multinational study on 426 previously untreated patients. Haematologica
87: 1258–1264
Primary mediastinal large B-cell lymphoma, chemotherapy
G Todeschini et al
376
British Journal of Cancer (2004) 90(2), 372–376 & 2004 Cancer Research UK
C
l
i
n
i
c
a
l